Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER in Schizophrenia
NCT00915512Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2009
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Johnson & Johnson. Primary endpoint: Personal and Social Performance at 12 months. Started May 2009; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00915512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00915512.